Zydus Lifesciences Ltd
NSE: ZYDUSLIFE BSE: 532321
â‚ą1188.10
-52.50 (4.23%)
Sat, 07 Nov 2026, 11:22 pm
Market Cap (in Cr)123590.72
PE Ratio26.48
Dividend0.08
Health Technology
Pharmaceuticals: Major
24.5KZydus Lifesciences Ltd Company History
1995
- Incorporated as Cadila Healthcare Private Ltd. on May 15.
- Signed agreement with Anda Biologicals, France, for diagnostic kits marketing.
1996
- Converted to public company and renamed Cadila Healthcare Ltd. effective July 17.
- Signed agreement with Centeon for plasma products rights in India and Nepal.
- Signed agreement with Acta Services for Acto 1 Analyser distribution.
- Signed agreement with China Resources Gulin Pharma for Artesunate Granules.
- Signed agreement with Shimizu Chemical Corporation for product marketing.
1997
- High Court of Gujarat sanctioned Scheme of Arrangement and Amalgamation.
- Issued 1,48,423 equity shares to Patel Group shareholders.
- Tied up with Regional Research Laboratory Jammu for Paroxetine HCL enzymatic resolution.
1998
- Signed agreement with Apotex SA Pty. Ltd. for manufacturing Amoxycillin, Ampicillin, Co-trimoxazole, and Paracetamol.
- Entered JV with Korea Green Cross Corporation for recombinant Hepatitis B vaccine.
1999
- Signed agreement with Ethical Holdings for transdermal formulations.
- Signed agreement with Cherry Valley Farms for vaccine eggs.
- Entered 50:50 JV with Byk Gulden for Pantoprazole.
- Issued 2,00,000 12% Cumulative Redeemable Preference shares.
- Indon Healthcare Limited and Zydus Aqrovet Limited became wholly owned subsidiaries.
- Planned Losartan manufacturing project at Ankleshwar.
- Laid foundation for feed supplement plant at Vatwa.
- Entered technical tie-up with Swiss Serum and Vaccine Institute for vaccines.
- Entered JV with Haffkine Institute for human vaccines and equine sera.
- Began setting up R&D centre at Moraiya for Rs. 25 crores.
- Launched Vac Typh, HB Vac, Xylodac, Losartan, and Matergam P.
- Set up manufacturing for Improval at GIDC Vatwa.
- Pranlal Bhogilal appointed additional Director on December 15.
- Introduced new employee welfare policy.
2000
- Company planned wholly owned subsidiaries abroad.
- Entered license agreement with Swiss Serum and Vaccine Institute for Purified Chick Embryo Vaccine.
- Launched two HIV drugs.
- Ankleshwar Bulk Drugs received ISO 9002 certification.
- Public issue of 1,48,86,000 equity shares.
- Authorised share capital increased to Rs 500 million.
- Recognized as Prestigious Unit for sales tax deferment.
- Zydus Pharmaceuticals Limited and Zoom Properties Limited became wholly owned subsidiaries.
- Formed Zydus Byk Healthcare JV with Byk Gulden.
- Formed Sarabhai Zydus Animal Health JV with Ambalal Sarabhai Enterprises.
- Launched Atorvastatin, Lamivudine, Celecoxib, Meloxicam, and Carvedilol.
- Acquired Recon Limited brands; Recon Healthcare Ltd. became subsidiary.
- Launched zidovudine as Zydowin.
- Launched www.penegra.org.
- Completed phase-III trials and bioequivalence study for sildenafil citrate.
2001
- Cadila Healthcare signed three-year R&D agreement with Pantheco for anti-bacterials.
- Neurosciences division launched paroxetine first in India.
2002
- Board approved issuance of Rs 700 million Secured Redeemable Non Convertible Debentures.
2003
- Upen Shah designated as Company Secretary.
- Zydus Cadila bagged global marketing rights for Vaxirab anti-rabies vaccine.
- Cadila Healthcare received Mumbai High Court approval for amalgamation with German Remedies Ltd. and Zoom Properties Ltd.
- Cadila Healthcare acquired Alpharma SAS France for Euro 5.5 million.
- H.K. Bilpodiwala, H. Dhanarajgir, and A.S. Diwanji appointed as additional directors.
- Zydus Cadila signed pact with Schering AG for patented products in India.
2004
- Zydus Cadila set up Zydus Pharmaceuticals USA, Inc.
- Zydus Cadila inked strategic pact with Boehringer Ingelheim.
- Zydus Altana Healthcare JV received ISO 9001-2000 accreditation.
2005
- Zydus Cadila received USFDA approval for Atenolol and Clindamycin.
- Zydus Cadila unveiled Pitavastatin.
- Cadila tied up with Tyco unit for generic drugs in US.
- Cadila Healthcare launched NuPatch Diclofenac transdermal patch.
- Cadila Healthcare and Mayne signed agreement for oncology JVC.
- Cadila Healthcare launched Fludara Oral.
- Zydus Cadila received tentative USFDA approval for Divalproex Sodium DR Tablets.
- Cadila Healthcare received USFDA approval for Promethazine Tablets.
- Cadila Healthcare entered JV with BSVL.
2006
- Zydus Cadila forged alliance with French firm.
- Zydus Cadila received USFDA approval for Simvastatin Tablets.
- Zydus Cadila planned to acquire Nutralite.
- Sarabhai Zydus planned to roll out immuno-diagnostics kits.
- Cadila Healthcare issued 1:1 bonus.
2007
- Cadila Healthcare acquired Nippon Universal Pharmaceutical Ltd.
- Cadila Healthcare acquired Quimica e Farmaceutica Nikkho do Brasil Ltda.
- Zydus Cadila launched anti-obesity drug Slimona first in India.
2008
- Zydus Cadila and Karo Bio signed research agreement for inflammatory disease drug.
- Zydus Cadila acquired Etna Biotech from Crucell N.V.
- Zydus Cadila launched Venlafaxine Hydrochloride in US on first day.
2009
- Zydus Cadila announced research collaboration for cardiovascular medicines.
- Zydus Research Centre received AAALAC Accreditation.
2010
- CHL announced bonus shares in 1:2 ratio.
- Cadila Healthcare developed and launched India's first indigenous H1N1 vaccine.
2011
- Company signed agreement with Bayer HealthCare for 50:50 JV Bayer Zydus Pharma.
- Cadila received USFDA nod for diabetes drug trial.
- Cadila Health acquired Bremer Pharma from ICICI Venture.
2012
- Cadila Healthcare entered settlement and license agreement with Somaxon for Silenor.
- Cadila Healthcare received USFDA approval for Aripiprazole orally disintegrating tablets.
2013
- Zydus Cadila received tentative USFDA approval for Doxepin HCl tablets.
- Zydus and IDRI signed agreement for Visceral Leishmaniasis vaccine candidate.
- Zydus and Pieris signed broad co-development alliance for Anticalin therapeutics.
- Zydus Pharmaceuticals (USA) Inc. signed agreement with Warner Chilcott Company LLC.
2014
- Zydus and Gilead entered generic licensing agreement for Hepatitis C treatment.
- Zydus launched world’s first biosimilar of Adalimumab.
- Cadila Healthcare launched Lipaglyn, India's first NCE.
2015
- Zydus Cadila completed single ascending dose study.
- Zydus launched SoviHep for Hepatitis C in alliance with Gilead Sciences.
- Cadila Healthcare purchased remaining 50% shares of Zydus BSV Pharma.
- Cadila Healthcare received final USFDA approval for Pyridostigmine Bromide Tablets.
- Cadila Healthcare received USFDA market authorisation for chronic pain drug.
- Cadila Healthcare received final USFDA approval for Amiloride Hydrochloride Tablets.
- Zydus launched Tenglyn gliptin.
- Cadila Healthcare split face value from Rs. 5 to Rs. 1.
2016
- Zydus Cadila acquired select animal health brands from Zoetis.
- Zydus received final USFDA approval for Glyburide and Metformin HCl Tablets.
- Zydus acquired gastro therapy Actibile from Albert David Limited.
- Zydus received USFDA approval for Glyburide Tablets.
- Zydus acquired two ANDAs from Teva.
- Zydus acquired six brands from MSD.
2017
- Zydus received final USFDA approval for Temozolomide Capsules and Nadolol Tablets.
- Zydus Cadila acquired Sentynl Therapeutics Inc.
- Zydus and Pharm Aid Ltd. entered exclusive agreement for vaccine technology in Russia.
- Zydus received EIR for manufacturing facility at Pharma SEZ Ahmedabad.
- Zydus received final USFDA approval for Desvenlafaxine Extended-Release Tablets.
- Cadila Healthcare entered agreement with Phibro Animal Health for poultry vaccine technologies.
2018
- Zydus Cadila received USFDA approval for sedative injection.
- Zydus entered agreement with Medicure International for pitavastatin NDA in US.
- Zydus Cadila received USFDA approval for Omeprazole and Sodium Bicarbonate Capsules.
- Zydus Cadila received approval for Carbidopa Tablets.
- CSIR-IMTECH inked pact with Zydus Cadila.
- Zydus Cadila launched generic erectile dysfunction drug in US.
2019
- Zydus launched Ramelteon Tablets for insomnia.
- Zydus received tentative USFDA approval for Lorcaserin Hydrochloride Tablets.
2020
- Zydus and CMS entered pact for Desidustat in Greater China.
- Zydus Wellness launched hand sanitizer under Nycil brand.
- Zydus Cadila launched COVID-19 drug Remdesivir in India.
- Zydus Cadila launched new product for COPD patients in India.
2021
- Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
- Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
- Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
- Zydus Group had 338 approvals and filed over 431 ANDAs.
- Zydus Life received final USFDA approval for Topiramate extended-release capsules.
- Zydus Lifesciences' arm received EC approval for MoCD injection.
- Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
- Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
- Zydus Lifesciences received USFDA approval for Acyclovir Cream.
- Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
- Zydus Lifesciences received 7th CSR Health Impact Award.
2024
- Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
- Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.
